MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Agenus Inc. (NASDAQ:AGEN)*
Organization & Developments: Agenus
Parents
Agenus Inc. (NASDAQ:AGEN)*
Children
*An experimental vaccine incorporating its immune-boosting technology provided significant protection against malaria in a study of young African children
*DEVELOPS NON-ABSORBED POLYMERIC DRUGS TO TREAT DISORDERS IN THE AREAS OF RENAL, CARDIOVASCULAR AND METABOLIC DISEASES.
*Expertise with cancer vaccines and heat shock proteins, and QS-21 Stimulon® adjuvant
2019: Agenus_Rinse, Wash and Repeat
2019: How I Am Playing Agenus_seekingalpha.com
2020: Agenus Approaches Stock-Propelling Events
2020: Agenus First Data From MK-4830: Another Reason To Buy
2020: Agenus Vs. Seattle Genetics Cervical Cancer Clinical Trial Results
2020: Agenus: A Buy With iNKT Therapy, MK-4830 Milestone
2020: Agenus: Serial Underperformer's Deep I-O Pipeline Approaching Key Inflection Points
2020: First QS-21 Royalty Payment Due to Agenus is Triggered
2020: With Multiple Late Stage Cancer Therapies, Agenus Inc. Offers The Best Risk/Reward Profile In Biotechnology
2021: Agenus A Buy On Coming 2021 Data, FDA Filings
2021: Agenus/Bristol Myers Squibb Deal Makes For A Strong Buy_seekingalpha.com
2021: Strong Buy: Agenus' iNKT Cell-Therapy Extubated 3 Of First 4 Severe COVID-19 Patients In P1 Trial
2022: Agenus: Advancement Of Botensilimab Could Create A Great Pivot Point_ seekingalpha.com
2022: Agenus: It's Always Tomorrow_seekingalpha.com
2022: Agenus: Perpetually Getting There_ seekingalpha.com
2023: Agenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific Program
2024: Agenus: 2024 May Finally Be The Year For A Major Turnaround_seekingalpha.com
2024: Agenus: A Would-Be Rockstar Held Back By Middling Financials
2024: Agenus: Cash Poor + Milestone Rich = Tough Slog Ahead
2024: Agenus: Taking Advantage Of The Risk-Reward Opportunity
2024: Bristol Myers returns TIGIT bispecific to Agenus, frees itself from $1B+ milestones
2025: Agenus: Big On BOT/BAL As Cash Burn And Catalysts Collide
2026: Agenus Inc. (AGEN) Shareholder/Analyst Call - Slideshow
Organization & Developments: Agenus Archives (2012-2018)
Jumps
*Key People: Agenus
Finance & Acquisitions: Agenus